VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Adenovirus

Table of Contents
  1. General Information
    1. NCBI Taxonomy ID
    2. Disease
    3. Introduction
  2. Vaccine Information
    1. Adenovirus Type 4 and Type 7 Vaccine, Live, Oral
  3. References
I. General Information
1. NCBI Taxonomy ID:
10508
2. Disease:
Respiratory infection
3. Introduction
Adenoviruses are a large group of DNA viruses with a distinguished experimental history, including contributions to the discovery of RNA splicing and the elucidation of central pathways in cell transformation. Some adenoviruses are human pathogens. They are also very much in vogue as potential vaccine and gene therapy vectors. Structure-based redesign of their cell-targeting and antigenic properties is therefore a desirable goal (Harrison, 2010).
II. Vaccine Information
1. Adenovirus Type 4 and Type 7 Vaccine, Live, Oral
a. Product Name:
Adenovirus Type 4 and Type 7 Vaccine, Live, Oral
b. Manufacturer:
Barr Labs, Inc.
c. Vaccine Ontology ID:
VO_0000096
d. CDC CVX code:
143
e. Type:
Live vaccine
f. Status:
Licensed
g. Location Licensed:
United States
h. Host Species for Licensed Use:
Human
i. Preparation
Virus is prepared in human-diploid fibroblast cell cultures (strain WI-38). The virus strains have not been attenuated. The virus is harvested and dried. The dry virus material includes monosodium glutamate, sucrose, D-mannose, D-fructose, dextrose, human serum albumin, potassium phosphate and plasdone C (FDA: Adenovirus Vaccine).
j. Immunization Route
orally
k. Storage
Store refrigerated between 2° and 8° C (35° and 46° F). Do not freeze (FDA: Adenovirus Vaccine).
l . Approved Age for Licensed Use
Approved for use in military populations 17-50 years of age (FDA: Adenovirus Vaccine).
m. Contraindication
Pregnancy, allergy to vaccine components, or inability to swallow tablets whole (FDA: Adenovirus Vaccine).
n. Description
Indicated for active immunization for the prevention of febrile acute respiratory disease caused by Adenovirus Type 4 and Type 7, virus strains have not been attenuated. The vaccine is composed of two tablets (one of Adenovirus type 4 and one Adenovirus type 7) designed to pass intact through the stomach and release the live virus in the intestine (FDA: Adenovirus Vaccine).
III. References
1. Baden et al., 2014: Baden LR, Walsh SR, Seaman MS, Johnson JA, Tucker RP, Kleinjan JA, Gothing JA, Engelson BA, Carey BR, Oza A, Bajimaya S, Peter L, Bleckwehl C, Abbink P, Pau MG, Weijtens M, Kunchai M, Swann EM, Wolff M, Dolin R, Barouch DH. First-in-Human Evaluation of a Hexon Chimeric Adenovirus Vector Expressing HIV-1 Env (IPCAVD 002). The Journal of infectious diseases. 2014; ; . [PubMed: 24719474].
2. FDA: Adenovirus Vaccine: FDA: Adenovirus Vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm247508.htm]
3. Harrison, 2010: Harrison SC. Virology. Looking inside adenovirus. Science (New York, N.Y.). 2010; 329(5995); 1026-1027. [PubMed: 20798308].
4. Kim et al., 2014: Kim E, Okada K, Beeler JA, Crim RL, Piedra PA, Gilbert BE, Gambotto A. Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model. Journal of virology. 2014; 88(9); 5100-5108. [PubMed: 24574396].
5. Tompkins et al., 2007: Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerging infectious diseases. 2007; 13(3); 426-435. [PubMed: 17552096].